107:
is given for localized disease. Radiation using multiple radiation fields is given if the disease has wider extent with grouped lesions. For the less common situation of more extensive disease (still confined to skin),
116:(IFN-α) and intralesional rituximab have been used. Approximately one-third of PCFCL relapse, usually in the skin; treatment is similar to initial management and overall survival remains excellent.
426:"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas"
132:, more than two skin lesions, and nodular lesions as three prognostic factors, that are used to assess a cutaneous lymphoma international prognostic index (CLIPI), which is
175:
510:
285:
Suárez AL, Pulitzer M, Horwitz S, et al. (2013). "Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification".
88:
150:
64:. It was recognized as a distinct disease entity in the 2008 WHO classification. PCFCL had been previously conceived as a variant of
465:
Suárez AL, Querfeld C, Horwitz S, et al. (2013). "Primary cutaneous B-cell lymphomas: part II. Therapy and future directions".
269:
237:
185:
92:
180:. World Health Organization classification of tumours. Vol. 2 (4th ed.). International Agency for Research on Cancer.
325:
Sokol L, Naghashpour M, Glass LF (2012). "Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management".
191:
128:
is excellent with a 5-year survival of over 97%. The
International Extranodal Lymphoma Study Group identified elevated
145:
77:
80:
although presence of that translocation does not exclude PCFCL. It is usually not associated with overexpressed
370:
129:
174:
Swerdlow, Steven H.; International Agency for
Research on Cancer; World Health Organization (2008).
155:
65:
403:
505:
482:
447:
395:
342:
302:
265:
233:
181:
46:
474:
437:
385:
334:
294:
113:
371:"Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management"
17:
499:
407:
104:
442:
425:
95:
are the other primary cutaneous B-cell lymphomas. The cause of PCFCL is unknown.
87:
PCFCL represents about 55% to 60% of primary cutaneous B-cell lymphomas (PCBCL);
478:
338:
298:
133:
125:
109:
486:
451:
399:
346:
306:
61:
390:
260:
Armitage, JO; Mauch PM; Harris NL; et al. (2010). "Chapter 24".
177:
WHO classification of tumours of haematopoietic and lymphoid tissues
81:
228:
Jaffe ES, Harris NL, Vardiman JW, Campo E, Arber, DA (2011).
76:
Unlike FL, PCFCL is not typically associated with t(14;18)
424:Senff NJ, Noordijk EM, Kim YH, et al. (2008).
264:(2nd ed.). Lippincott Williams & Wilkins.
45:
37:
32:
255:
253:
251:
249:
223:
221:
219:
217:
215:
213:
211:
209:
207:
205:
203:
201:
8:
364:
362:
360:
358:
356:
112:without chemotherapy is used. Intralesional
93:diffuse large B-cell cell lymphoma, leg type
419:
417:
320:
318:
316:
58:Primary cutaneous follicle center lymphoma
33:Primary cutaneous follicle center lymphoma
29:
441:
389:
124:Spread from the skin is unusual, and the
89:primary cutaneous marginal zone lymphoma
166:
151:Primary cutaneous large B-cell lymphoma
511:Lymphoid-related cutaneous conditions
7:
232:(1st ed.). Elsevier Saunders.
25:
1:
473:(3): 343.e1–11, quiz 355–6.
443:10.1182/blood-2008-04-152850
293:(3): 329.e1–13, quiz 341–2.
527:
479:10.1016/j.jaad.2013.06.011
339:10.1177/107327481201900308
299:10.1016/j.jaad.2013.06.012
18:Follicular center lymphoma
146:Cutaneous B-cell lymphoma
136:of disease-free status.
103:Surgical removal and/or
467:J. Am. Acad. Dermatol
287:J. Am. Acad. Dermatol
262:Non-Hodgkin Lymphomas
194:on October 12, 2013.
156:Follicular lymphoma
66:follicular lymphoma
51:Hematology/oncology
369:Wilcox RA (2015).
391:10.1002/ajh.23863
55:
54:
27:Medical condition
16:(Redirected from
518:
491:
490:
462:
456:
455:
445:
421:
412:
411:
393:
375:
366:
351:
350:
322:
311:
310:
282:
276:
275:
257:
244:
243:
225:
196:
195:
190:. Archived from
171:
114:interferon alpha
30:
21:
526:
525:
521:
520:
519:
517:
516:
515:
496:
495:
494:
464:
463:
459:
423:
422:
415:
373:
368:
367:
354:
324:
323:
314:
284:
283:
279:
272:
259:
258:
247:
240:
230:Hematopathology
227:
226:
199:
188:
173:
172:
168:
164:
142:
122:
101:
74:
28:
23:
22:
15:
12:
11:
5:
524:
522:
514:
513:
508:
498:
497:
493:
492:
457:
413:
378:Am. J. Hematol
352:
327:Cancer Control
312:
277:
270:
245:
238:
197:
186:
165:
163:
160:
159:
158:
153:
148:
141:
138:
121:
118:
100:
97:
73:
70:
53:
52:
49:
43:
42:
39:
35:
34:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
523:
512:
509:
507:
504:
503:
501:
488:
484:
480:
476:
472:
468:
461:
458:
453:
449:
444:
439:
436:(5): 1600–9.
435:
431:
427:
420:
418:
414:
409:
405:
401:
397:
392:
387:
383:
379:
372:
365:
363:
361:
359:
357:
353:
348:
344:
340:
336:
333:(3): 236–44.
332:
328:
321:
319:
317:
313:
308:
304:
300:
296:
292:
288:
281:
278:
273:
271:9780781791168
267:
263:
256:
254:
252:
250:
246:
241:
239:9780721600406
235:
231:
224:
222:
220:
218:
216:
214:
212:
210:
208:
206:
204:
202:
198:
193:
189:
187:9789283224310
183:
179:
178:
170:
167:
161:
157:
154:
152:
149:
147:
144:
143:
139:
137:
135:
131:
127:
119:
117:
115:
111:
106:
98:
96:
94:
90:
85:
83:
79:
78:translocation
71:
69:
67:
63:
60:is a type of
59:
50:
48:
44:
40:
36:
31:
19:
470:
466:
460:
433:
429:
381:
377:
330:
326:
290:
286:
280:
261:
229:
192:the original
176:
169:
123:
105:radiotherapy
102:
86:
75:
57:
56:
384:(1): 73–6.
38:Other names
500:Categories
162:References
134:prognostic
126:prognosis
120:Prognosis
110:rituximab
99:Treatment
47:Specialty
506:Lymphoma
487:23957985
452:18567836
408:10733762
400:25535037
347:22710899
307:23957984
140:See also
62:lymphoma
68:(FL).
485:
450:
406:
398:
345:
305:
268:
236:
184:
430:Blood
404:S2CID
374:(PDF)
82:Bcl-2
72:Cause
41:PCFCL
483:PMID
448:PMID
396:PMID
343:PMID
303:PMID
266:ISBN
234:ISBN
182:ISBN
91:and
475:doi
438:doi
434:112
386:doi
335:doi
295:doi
130:LDH
502::
481:.
471:69
469:.
446:.
432:.
428:.
416:^
402:.
394:.
382:90
380:.
376:.
355:^
341:.
331:19
329:.
315:^
301:.
291:69
289:.
248:^
200:^
84:.
489:.
477::
454:.
440::
410:.
388::
349:.
337::
309:.
297::
274:.
242:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.